Association of *SDF-1* Gene Polymorphism with Increased Risk of Acute Myeloid Leukemia Patients

Doaa Abd Allah M Aladle¹, Mayada A Ghannam¹, Shaimaa El-Ashwah², F E I Ghobrial³, Metwaly Ibrahim Mortada*¹

Abstract

**Background:** Acute myeloid leukemia (AML) is a heterogeneous group of disorders that emerge from the malignant transformation of hematopoietic stem cells. Chemokine stromal cell-derived factor 1 (SDF-1) and its receptor CXC receptor 4 (CXCR4) has an essential role in dissemination of blast cells. Study aimed to detect CXCR4 expression and the *SDF-1* (rs1801157) gene polymorphisms and correlate them with prognosis and outcome in AML patients. **Subjects and Methods:** The study was conducted on 60 de-novo AML patients, and 60 healthy controls. *SDF-1* (rs1801157) gene polymorphisms were detected by polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP), and CXCR4 expression was done using flow cytometry analysis. **Results:** SDF-1 dominant model (AG+AA) had higher risk AML (p 0.002). CXCR4 positive cases were associated significantly with toxic manifestations (p 0.019), lower CR rates (p 0.004), and unfavorable cytogenetics (p 0.027). Multivariate analysis showed that combined CXCR4-positive with dominant SDF-1 considered as independent prognostic factor for shorter overall survival (OS) in AML patients (p 0.031). **Conclusion:** SDF-1 dominant model had a higher risk to develop AML, and CXCR4 positive expression predicts poor prognosis in AML patients and it could represent a targeted therapy in AML. In addition, CXCR4 could be easily integrated into the initial routine diagnostic work up of AML.

**Keywords:** Acute myeloid leukemia- *SDF-1*- CXCR4- PCR-RFLP

*Asian Pac J Cancer Prev, 22 (4), 1035-1043*
Materials and Methods

Subjects

A study was conducted on 60 patients with de novo acute myeloid leukemia patients were diagnosed at the Oncology Center Mansoura University (OCMU). Their ages ranged between 19 and 70 years and apparently healthy 60 individuals were also included as a control group. All data were collected regarding history and examination. Laboratory procedures were performed in clinical pathology labs of OCMU. Induction therapy was based on age and performance status as fit patients treated by 3+7 and consolidation by high dose Ara C, while frail one by low dose cytarabine or hypomethylating agents. The study excluded the patients with acute promyelocytic leukemia, secondary AML and childhood AML.

A) Routine work: (1) Complete blood count (Hemogram): using the electronic counter (CELL-DYN 3700, Abbott, Canada) with thorough examination of peripheral blood smears stained with leishman stain. (2) Liver function tests, serum creatinine, serum uric acid test, and serum LDH.

B) Work up for AML diagnosis: (1) Microscopic study of bone marrow slides. (2) Cytochemistry: e.g. MPO, PAS, and NSE. (3) Immunophenotyping (IPT) using American BD flow-cytometer device to diagnose the cases and exclude the other types of leukemia by using cell surface marker including myeloid and lymphoid lineage. Positivity in each marker can be calculated if it is more than 20%. (4) Fluorescence in situ hybridization (FISH).

C) Specific work up: (1) Detection of (SDF-1 G801A, rs 1801157) gene polymorphisms by polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) assay (for patients and controls). (2) Detection of CXCR4 receptor expression by flow cytometry (for patients only).

Methods

I- Detection of (SDF-1 G801A, rs 1801157) gene polymorphisms by PCR-RFLP

Sampling: Two milliliters put in tube containing anticoagulant (EDTA) to genomic DNA extraction preparing for investigation (SDF-1 G801A, rs 1801157) polymorphisms by PCR-RFLP test.

DNA extraction: Done by Gene JET Whole Blood Genomic DNA Purification Mini Kit (#K0781).

PCR reaction: The test was done in 3 steps: (1) Amplification of extracted genomic DNA. (2) The amplified product is then digested by a suitable restriction enzyme. (3) Detection of the digested products using gel electrophoresis and ultraviolet light transillumination.

The electronic warm cycler might have been programmed to the emulating states to SDF-1 G801A gene polymorphisms those accompanying cycles were utilized: a beginning high temperature—activation step at 95 °C for 10 minutes, denaturation toward 95 °C to 1 min then last development in 72°C for 10 minutes.

- For (SDF-1 G801A, rs 1801157) gene polymorphisms, the following primers were used:
  - Forward primer: 5’ CAG TCA ACC TGG GCA AAG CC 3’.
  - Reverse primer: 5’ AGC TTT GGT CCT GAG AGT CC 3’.

- PCR products were digested at 37°C with 10U MspI resulting in generation of two fragments of 202-bp and 100-bp after digestion in the presence of the G allele and it is designated GG, wild type (i.e. homozygous for the presence of restriction site), if the A allele exists at position 801, no digestion occurred and only one 302 bp band will emerge and it is designated AA (i.e. homozygous for the absence of the restriction site), if the 3 bands 302,202and 100 bp are present it is designated AG (i.e. heterozygous).

II- Detection of CXCR4 receptor expression by Flow cytometry and a cut off equals to 20.0% was used.

Sampling Bone marrow aspirate or venous blood samples examined for CXCR4 expression by flow cytometry (BD FACSCANTOII), generally within 2 to 4 hours after the sample was drawn.

principle: Washed cells were incubated with the fluorescein labeled monoclonal antibody [Phycoerythrin (PE) Mouse Anti-Human CD184 monoclonal antibody (#561733) (BD Biosciences, San Diego, CA)], which attach to the cells with express the CXCR4 receptor. Unbound fluorescein-conjugated antibodies were at that point washed from the cells. Cells with express the CXCR4 receptor are fluorescently stained, with the intensity of staining directly proportional to the density of the CXCR4. Cell surface expression of the CXCR4 was decided by cytometric examination using 488 nm wavelength laser excitation.

Statistical Analysis

The statistical analysis of data was done using SPSS (statistical package for social science program (SPSS, Inc, Chicago, IL) version 20. Qualitative data were presented as frequency and percentage. Chi square and Fisher’s exact tests were used to compare groups. Quantitative data were presented by mean, SD or median and range. Comparisons between two groups were done using t-test or Man Whitney (for non-parametric data), while comparison between more than two groups were done using ANOVA or Kruskal Wallis tests (for non-parametric data). The OR and 95% confidence interval (95% CI) obtained from the logistic regression were used Kaplan–Meier test was used for survival analysis and the statistical significance of C among curves was determined by Log-Rank test. Cox regression analysis was used for prediction of OS. P value is significant if <0.05 at confidence interval 95%.

Sample size

Sample size is calculated using online sample size calculator (http://osse.bii.a-star.edu.sg/calculation1.php) with genotype polymorphism of SDF1 (Aisha et al., 2010) and level of absolute precision of 2% at alpha error of 5% and study power of 80%. A minimal sample size required for the study is calculated to be 54 subjects for each group. To account for possible, drop out a total sample of 60 subjects in each group is initially planned to be included in the study.
Results

Our study included 60 new AML cases and 60 healthy control. Comparison between control and AML patients are summarized in Table 1.

CXCR4 was measured by flow cytometry and a cut off equals to 20.0% was used, so that values ≥ 20.0% were considered CXCR4 positive, while those below this level were considered CXCR4 negative Table (2). Negative and Positive flow cytometric analysis of CXCR4 expression on AML myeloblast cells are shown in Figures 1 and 2.

SDF-1 (A) and (G) allele carrier frequencies show significant differences in patients versus controls (p 0.002). Carrying A allele had higher risk to develop AML (OR 3.134, 95% CI 1.521-6.459). When combining both hetero- and homozygous (AG+AA) groups; there was significant difference in patients versus control subjects (p 0.002). SDF-1(rs1801157) dominant model (AG+AA) had higher risk to develop AML (OR 3.500, 95%CI=1.555-7.874) Table (3). RFLP analysis of SDF-1 (G801A, rs 1801157) gene polymorphisms in AML patients is shown in Figure 3.

CXCR4positive cases were associated significantly with toxic manifestations (p 0.019) and lower CR rates (p 0.004) compared to those with CXCR4negative. Notably, it was found that 75% of CXCR4positive and 64.3% of SDF-1 (A) allele genotype were AML M4/ M5 patients. Patients with positive CXCR4 had higher unfavorable cytogenetics when compared to those with negative CXCR4 (58.3% vs 27.8%, p 0.027). No statistically significant differences between different SDF-
1 genotypes as regard clinical presentation, cytogenetic risk stratification, and outcome Table 4.

When stratifying AML into 4 groups according CXCR4 positivity and SDF1 gene polymorphisms, CXCR4 positive with SDF-1 (A) allele carrier genotype AML patients had significantly higher incidence of toxic manifestations (p 0.023) and lower CR (p 0.016) versus CXCR4 negative with SDF-1 (G/G) alleles genotype AML patients and discordant respectively. Otherwise, no significant differences were found regarding other parameters. As regard clinical outcome of AML cases according to combined CXCR4 positivity and SDF-1

![Image](image-url)

**Figure 2.** Positive Flow Cytometric Analysis of CXCR4 Expression on AML Myeloblast Cells. Flow cytometric analysis of CXCR4 expression on AML myeloblast cells. These results were obtained from a patient with newly diagnosed acute myeloblastic leukemia (FAB-M2 AML). CXCR4 (CD184 PE) expression was measured on myeloblast populations after setting a gate on side scatter (SSC)/anti-CD45 APC scatter graph, completed with CD34 expression to optimize myeloblast gating. Expression was positive in this case = 84.2%.

| Table 4. Clinical Characteristics of Studied AML Cases According to CXCR4 Positivity and SDF-1 Genotypes. |
|---------------------------------------------------------------|
| Clinical data | CXCR4 expression | P | SDF-1 genotypes | p |
| | Negative (n=36) | Positive (n=24) | | GG (n=32) | (A) allele carrier (n=28) |
| | No | % | No | % | No | % | No | % |
| Age | | | | | | | | |
| Age <60 | 29 | 80.6 | 23 | 95.8 | 0.128 | 26 | 81.3 | 26 | 92.9 | 0.264 |
| Age ≥60 | 7 | 19.4 | 1 | 4.2 | 6 | 18.8 | 2 | 7.1 | |
| TLCx10^9/l | | | | | | | | |
| Median | 54 | 64 | 0.251 | 57 | 59 | 0.87 |
| Min - Max | 1-236 | 1-214 | 3-207 | 1-236 |
| BM blast cells | | | | | | | | |
| Median | 92 | 93.5 | 0.221 | 90 | 92 | 0.3 |
| Min - Max | 23-100 | 28-100 | 23-100 | 33-99 |
| FAB classification | | | | | | | | |
| M1/M2 | 12 | 33.3 | 6 | 25 | 0.145 | 10 | 31.3 | 8 | 28.6 | 0.97 |
| M4-5 | 20 | 55.6 | 18 | 75 | 20 | 62.5 | 18 | 64.3 |
| M7 | 4 | 11.1 | 0 | 0 | 2 | 6.3 | 2 | 7.1 |
| Clinical presentation | | | | | | | | |
| Toxic manifestations (n=34) | 16 | 44.4 | 18 | 75 | 0.019 | 15 | 46.9 | 19 | 67.9 | 0.102 |
| Extramedullary infiltration (EMI) (n=51) | 28 | 77.8 | 23 | 95.8 | 0.072 | 27 | 84.4 | 24 | 85.7 | 0.885 |
| Cytogenetics risk stratification | | | | | | | | |
| Favorable | 17 | 47.2 | 4 | 16.7 | 12 | 37.5 | 9 | 32.1 | 0.488 |
| Intermediate | 9 | 25 | 6 | 25 | 6 | 18.8 | 9 | 32.1 |
| Unfavorable | 10 | 27.8 | 14 | 58.3 | 0.027 | 14 | 43.8 | 10 | 35.8 |
| Response rate | | | | | | | | |
| CR | 16 | 44.4 | 2 | 8.3 | 0.004 | 8 | 25 | 10 | 35.7 | 0.366 |
| Non-CR (RD-ID) | 20 | 55.6 | 22 | 91.7 | 24 | 75 | 18 | 64.3 |

CR, Complete response; ID, Induction death; RD, Refractory disease; TLC, Total leucocytic count.
genotypes, no significant differences between the 4 groups and between CXCR4 negative with SDF1 (G/G) alleles genotype AML patients versus disconcordant versus CXCR4 positive with SDF-1(A) allele carrier genotype AML patients were found in clinical outcome Table 5.

There was no statistically significant difference in OS and DFS as regarding CXCR4 expression (p 0.092 and 0.9 respectively). In addition, there was no significant difference was found in OS between SDF1 GG versus SDF1 AG+AA genotypes (p 0.113). Patients with CXCR4 positive and SDF1 (AA /AG) had higher risk to have shorter OS (HR 3.891, 95% CI 1.389-10.899, p 0.01) Figure (4and5). Patients with favorable cytogenetics had longer OS than those intermediate and unfavorable cytogenetics (5.418 versus 2.358, 2.111 months respectively, p 0.001), Figure 6.

Table 5. Clinical Characteristics of Studied AML Cases According to Combined CXCR4 Positivity and SDF-1 Gene Polymorphisms

| Clinical data                  | CXCR4<sup>positive</sup> and SDF-1 GG (n=17) | CXCR4<sup>positive</sup> and SDF-1 AG+AA (n=19) | CXCR4<sup>positive</sup> and SDF-1 GG (n=15) | CXCR4<sup>positive</sup> and SDF-1 AG+AA (n=9) | P*  | P<sup>^</sup> |
|-------------------------------|-----------------------------------------------|-----------------------------------------------|-----------------------------------------------|-----------------------------------------------|-----|-----|
| Age                           |                                               |                                               |                                               |                                               |     |     |
| <60                           | 12 70.6                                       | 17 89.5                                       | 14 93.3                                       | 9 100                                        | 0.117 | 0.055 |
| ≥60                           | 5 29.4                                       | 2 10.5                                       | 1 6.7                                        | 0 0                                          |     |     |
| TLC x 10<sup>9</sup>/l         |                                               |                                               |                                               |                                               |     |     |
| Median                        | 33 57                                        | 64 31                                         | 31                                            |                                               | 0.391 | 0.296 |
| BM blast cells                |                                               |                                               |                                               |                                               |     |     |
| Median                        | 90 92                                        | 92 95                                         | 95                                            |                                               | 0.382 | 0.219 |
| FAB                           |                                               |                                               |                                               |                                               |     |     |
| M1/M2                         | 6 35.3                                       | 6 31.6                                       | 4 26.7                                       | 2 22.2                                       | 0.675 | 0.693 |
| M4-5                          | 9 52.9                                       | 11 57.9                                      | 11 73.3                                      | 7 77.8                                       |     |     |
| M7                            | 2 11.8                                       | 2 10.5                                       | 0 0                                          | 0 0                                          |     |     |
| Clinical presentation         |                                               |                                               |                                               |                                               |     |     |
| Toxic manifestations (n=34)    | 5 29.4                                       | 11 57.9                                      | 10 66.7                                      | 8 88.9                                       | 0.023 | 0.01 |
| EMI (n=51)                    | 12 70.9                                      | 16 84.2                                      | 15 100.0                                    | 8 88.9                                       | 0.137 | 0.143 |
| Cytoeugenetics risk stratification |                                               |                                               |                                               |                                               |     |     |
| Favorable (n=21)              | 9 53                                          | 8 42.1                                       | 3 20.0                                       | 1 11.2                                       | 0.099 | 0.174 |
| Intermediate (n=15)           | 4 23.5                                       | 5 26.3                                       | 2 13.3                                       | 4 44.4                                       |     |     |
| Unfavorable (n=24)            | 4 23.5                                       | 6 31.6                                       | 10 66.7                                      | 4 44.4                                       |     |     |
| Response rate                 |                                               |                                               |                                               |                                               |     |     |
| CR                            | 8 47.1                                       | 8 42.1                                       | 0 0                                          | 2 22.2                                       | 0.016 | 0.193 |
| Non-CR (ID and RD)            | 9 52.9                                       | 11 57.9                                      | 15 100                                       | 7 77.8                                       |     |     |

P*, significance between 4 groups; P<sup>^</sup>, significance between CXCR4 negative with SDF1(G/G) alleles genotype AML patients vs disconcordant vs CXCR4 positive with SDF-1(A) allele carrier genotype AML patients; CR, Complete response; ID, Induction death; RD, Refractory disease; EMI, Extra medullary infiltration.
Table 6. Multivariate Analysis for OS and DFS in AML Patients

| Covariates                        | OS  | DFS  |
|-----------------------------------|-----|------|
|                                   | P   | HR   | 95% CI   | P   | HR   | 95% CI   |
| Age (years)                       | 0.043 | 1.032 | 1.001-1.065 | 0.245 | 0.832 | 0.609-1.135 |
| Marrow blast (%)                  | 0.052 | 1.027 | 0.998-1.054 | 0.585 | 1.021 | 0.948-1.099 |
| Combined CXCR4 expression & SDF-1 polymorphism |     |      |           |     |      |           |
| CXCR4neg and SDF-1 GG             | -   | 1    | Reference | -   | 1    | Reference |
| CXCR4neg and SDF-1 AG+AA          | 0.071 | 2.712 | 0.917-8.026 | 0.132 | 2.877 | 0.202-2.119 |
| CXCR4pos and SDF-1 AA             | 0.111 | 2.587 | 0.804-8.326 | 0.18  | 1.703 | 0.055-5.226 |
| CXCR4pos and SDF-1 AG+AA          | 0.031 | 4.274 | 1.161-15.738 | 0.872 | 0.575 | 0.001-4.133 |
| Cytogenetic risk stratification   |     |      |           |     |      |           |
| Favorable                         | 0.003 | 3.701 | 1.544-8.871 | 0.135 | 0.956 | 0.784-1.125 |
| Intermediate                      |     |      |           |     |      |           |
| Unfavorable                       | 0.001 | 4.165 | 1.840-9.427 | 0.834 | 0.849 | 0.183-3.937 |

CI 95%, Confidence interval at 95%; OS, Overall survival; DFS, Disease free survival; HR, High risk.

Prediction of survival was done using cox regression analysis applying age, marrow blasts, and combined CXCR4 expression and SDF-1 genotypes as covariates and cytogenetics. Multivariate analysis showed that combined CXCR4 positive with SDF-1 (AG + AA) which reached statistical significance and considered as independent prognostic factor for AML patients (p 0.031). Patients with positive CXCR4 and SDF-1 (AG + AA) had higher risk to have shorter OS (HR 4.274, 95% CI 1.161-15.738). Age is still also independent risk factor for shorter OS (p 0.043). Also, intermediate and unfavorable outcome are independent risk factors for shorter OS (HR 4.165, 95% CI 1.184-9.427, p 0.001) respectively Table 6.

Discussion

The interaction between leukemia cells and the bone marrow (BM) microenvironment is considered the major factor for development of chemotherapy resistance and disease relapse in leukemia. The CXCR4/SDF-1α axis played an essential role in the crosstalk between leukemia cells and BM microenvironment (Gualberto et al., 2017).

CXCR4 expression has been well studied in a different hematological and non-hematological malignancies e.g. chronic lymphocytic leukemia, myelodysplastic syndrome, multiple myeloma, pediatric AML, lung cancer, ovarian cancer, and breast cancer, in which it has been associated with adverse clinical outcomes, invasion, chemotherapy resistance, and metastasis (Cao et al., 2019).

SDF-1 SNP researches have been conducted for several
cancer types, but the results were conflicted based on the different studied population races, and cancer biology (Du et al., 2019).

The aim of this work is to study the expression of \textit{CXCR4} by flow cytometry and the \textit{SDF-1} gene polymorphisms by PCR-RFLP, and its relation to the clinical characteristics, patient prognosis and outcome.

In our study, there was significant difference between \textit{SDF-1} (rs 1801157) genotype expression in AML group and control subjects, as SDF-1 dominant model (AG or AG+AA) had higher risk to develop AML (p 0.002). The results of the current study cope with other meta-analysis studies reported by Meng et al., (2015); Zhang et al., (2017) and Tong et al., (2016) that found also association between \textit{SDF-1 G801A} polymorphisms and development of hematological malignancies especially AML. In contrast; Zheng et al., (2016); El-Ghany et al., (2014) studied the \textit{SDF-1 G801A} polymorphism in 466 and 48 adult de novo AML patients respectively, reported no significant difference in genotype distributions and allele
frequency between AML patients and healthy controls.

As regard CXCR4, our studied cases were classified into 36 cases (60.0%) had negative CXCR4 expression, their values ranged from 2 to 18; and 24 cases (40.0%) had positive CXCR4 expression, their values ranged from 21 to 84. Abd El-Rahman et al., (2010), reported that, 55% of the patients were CXCR4positive while 45% were CXCR4 negative expression on their blasts. The results were stated as the percentage of blasts co-expressing CXCR4 and CD34 within the gated population of blast cells with cut off value at 20%.

Our data showed no statistically significant differences regarding age and hematological laboratory data among CXCR4 positive and CXCR4 negative AML patients. While, toxic manifestations had significantly higher incidence in CXCR4 positive cases (p 0.019) compared to CXCR negative and also with combined CXCR4positive – SDF-1 (AA/AG) genotype AML patients (p 0.023) versus CXCR-negative, or CXCR4positive with SDF-1 (GG) genotype AML patients. Also, we found that that 75% of positive CXCR4 and 64.3% of SDF-1 (A) allele genotype were AML M4/5 patients, however p values were insignificant. Cao et al., (2019) showed that patients with FAB subtypes M4/5 had significantly higher CXCR4 expression than patients with other FAB subtypes.

Our results showed that CXCRPositive and Combined CXCRpositive and SDF1-(A) allele carrier genotype AML patients were associated with higher frequency of extra medullary infiltration (EMI) than the other group, however, p values were insignificant; 0.07, 0.137 respectively when compared to other groups. Similar Studies on acute leukemia showed that CXCR4 positivity and polymorphism in the SDF-1 coding gene (SDF-1 G801A) were associated with a higher frequency of extramedullary leukemic infiltration (Crazzolara et al., 2001; Liu et al., 2006).

The present study showed that patients with CXCR4 positive had unfavorable cytogenetic risk and lower CR rates compared to those with CXCR4negative (p 0.027 and 0.004 respectively). Also, Abd El-Rahman et al., (2010) demonstrated that, in CXCR4positive group, 73% of patients had unfavorable prognosis compared to 27% in CXCR4negative group.

Du et al., (2019) reported that SDF1/ CXCR4 axis may protect the leukemia cells from the chemotherapy effect by intrinsic immune regulation, through secretion of cytokines that suppress apoptosis and decreasing the sensitivity to chemotherapy.

Disruption of SDF-1/CXCR4 pathway is a key step in cytokine-induced hematopoietic stem cells mobilization from BM to peripheral blood. Plerixafor is a novel strategy of sensitizing myeloblast cells by targeting their protective BM microenvironment (Domingues et al., 2017).

In our study, prediction of survival by multivariate analysis showed that combined positive CXCR4 and SDF-1 dominant model (AG+AA) had higher risk to have shorter OS (HR 4.274, 95% CI 1.161-15.73, p 0.031) and age is still independent risk factor for shorter OS. Also, intermediate and unfavorable cytogenetic risk are independent risk factors for shorter OS (HR 3.701, 95% CI 1.544-8.871, p 0.003), (HR 4.165, 95% CI 1.184-9.427, p 0.001) respectively.

In multivariate Cox regression analysis done by Spoo et al., (2007) only unfavorable cytogenetics and CXCR4 expression by AML cells were significant predictive factors for poor OS. Also, CXCR4 expression was a significant predictor for relapse free survival. Similarly, Konoplev et al., (2007), proved the prognostic value of CXCR4 expression to be independent of other previously established prognostic markers such as age.

From this study, we could conclude that SDF-1 dominant model (AG+AA) had a higher risk to develop AML and that CXCR4 expression predicts poor prognosis in AML patients and it could represent a novel target for the effective treatment of AML. Finally, CXCR4 could be easily incorporated into the initial routine diagnostic work-up of AML patients.

Author Contribution Statement

Doaa Abd Allah M Aladle, Metwaly Ibrahim Mortada, Mayada A. Ghannam –equally participated in conception, interpretation of laboratory data and practical work. Shaimaa El-Ashwah, F.E.I. Ghobrial- collecting clinical data and statistical analysis. All authors - contributing to the study design, participated in writing and editing the final version of the manuscript, read and approved the final manuscript.

Acknowledgments

The authors would like to thank the chemists and technicians in Flowcytometry and Molecular Hematology laboratory at Oncology Center, Mansoura University (OCMU) laboratories.

This work was not a part of student thesis and was not funded.

Ethics approval

This study was approved by the institutional research committee of the investigating hospital Institutional Review Board (IRB), Mansoura Faculty of Medicine, number (R/19.02.436) and the 1964 Helsinki Declaration and its later amendments or comparable ethics standards.

Conflict of interest

The authors declare that there is no any conflict of interest.

References

Abd El-Rahman A, Abdel-Hamid S, Makhlouf M, et al (2010). Detection of CXCL12 gene polymorphism and CXCR4 expression in Egyptian acute myeloid leukemia patients. J Am Sci. 6, 318–30.

Cao T, Ye Y, Liao H, et al (2019). Relationship between CXC chemokine receptor 4 expression and prognostic significance in acute myeloid leukemia. Medicine. 98, 23.

Cao T, Jiang N, Liao H, et al (2019). The FLT3-ITD mutation and the expression of its downstream signaling intermediates STAT5 and Pim-1 are positively correlated with CXCR4 expression in patients with acute myeloid leukemia. Sci Rep, 9, 1-10.
Cho BS, Kim HJ, Konopleva M (2017). Targeting the CXCL12/CXCR4 axis in acute myeloid leukemia: from bench to bedside. *Korean J Int Med*, **32**, 248

Crazzolara R, Kreacey A, Mann G, et al (2001). High expression of the chemokine receptor CXCR4 predicts extramedullary organ infiltration in childhood acute lymphoblastic leukaemia. *Br J Haematol*, **115**, 545-53

Domingues MJ, Nilsson SK, Cao B (2017). New agents in HSC mobilization. *Int J Hematol*, **105**, 141-52

Du W, Lu C, Zhu X, et al (2019). Prognostic significance of CXCR4 expression in acute myeloid leukemia. *Cancer Med*, **8**, 6595-603

El-Ghany HM, El-Saadany ZA, Bahaa NM, Ibrahim NY, Hussien SM (2014). Stromal cell derived factor-1 (CXCL12) chemokine gene variant in myeloid leukemias. *Clin Lab*, **60**, 735-41

Fujita M, Davari P, Takada YK, Takada Y (2018). Stromal cell-derived factor-1 (CXCL12) activates integrins by direct binding to an allosteric ligand-binding site (site 2) of integrins without CXCR4. *Biochem J*, **475**, 723-32

Gualberto A, Scholz C, Janes MR, Kessler L, Raza A (2017). The CXCL12/CXCR4 pathway as a potential target of tipifarnib in acute myeloid leukemia and myelodysplastic syndromes. *Blood*, **130**, 3957

Hu X, Mei S, Meng W, et al (2018). CXCR4-mediated signaling regulates autophagy and influences acute myeloid leukemia cell survival and drug resistance. *Cancer Lett*, **425**, 1-12

Konoplev S, Rassidakis GZ, Estey E, et al (2007). Overexpression of CXCR4 predicts adverse overall and event-free survival in patients with unmutilated FLT3 acute myeloid leukemia with normal karyotype. *Cancer*, **109**, 1152-6

Liu ZR, Sun H, Zou P (2006). Expression of SDF-1alpha and its receptor CXCR4 in acute leukemias and their relationship with extramedullary infiltration. *Zhongguo Shi Yan Xue Za Zhi*, **14**, 1-5

Meng D, Wu YX, Heerah V, et al (2015). CXCL12 G801A polymorphism and cancer risk: An updated meta-analysis. *J Huazhong Univ Sci Technol [Medical Sciences]*, **35**, 319-26

Meng W, Xue S, Chen Y (2018). The role of CXCL12 in tumor microenvironment. *Gene*, **641**, 105-10

Mollica Poeta V, Massara M, Capucetti A, Bonecchi R (2019). Chemokines and chemokine receptors: new targets for cancer immunotherapy. *Front Immunol*, **10**, 379

Peled A, Klein S, Beider K, Burger JA, Abraham M (2018). Role of CXCL12 and CXCR4 in the pathogenesis of hematological malignancies. *Cytokine*, **109**, 11-6

Pillozzi S, Bernini A, Spiga O, et al (2019). Peptides and small molecules blocking the CXCR4/CXCL12 axis overcome bone marrow induced chemoresistance in acute leukemias. *Oncol Rep*, **41**, 312-24

Spoo AC, Lübbert M, Wierda WG, Burger JA (2007). CXCR4 is a prognostic marker in acute myelogenous leukemia. *Blood*, **109**, 786-91

Thakral D, Gupta R (2019). Acute Myeloid Leukemia: An Update. In Hematopathology. Springer, Singapore, pp 163-82

Tong X, Ma Y, Deng H, et al (2016). The SDF-1 rs1801157 polymorphism is associated with cancer risk: an update pooled analysis and FPRP test of 17,876 participants. *Sci Rep*, **6**, 1-10

Tuzuner NN, Bennett JM (2018). Classification of the acute leukemias: cytochemical and morphologic considerations. In Neoplastic Diseases of the Blood. Springer, Cham, pp 197-236

Zhang X, Fan Y, Li Z (2017). SDF1-3’ A polymorphism is associated with increased risk of hematological malignancy: a meta-analysis. *OncoTargets Ther*, **10**, 1575

Zheng Q, Shuai X, Ye Y, et al (2016). The role of polymorphisms of stromal-derived factor-1 and CXC receptor 4 in acute myeloid leukemia and leukemia cell dissemination. *Gene*, **588**, 103-8.